share_log

RBC Capital Maintains Outperform on Xenon Pharmaceuticals, Raises Price Target to $56

Benzinga ·  Nov 28, 2023 04:31

RBC Capital analyst Brian Abrahams maintains Xenon Pharmaceuticals (NASDAQ:XENE) with a Outperform and raises the price target from $51 to $56.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment